Senseonics (NYSE:SENS) Trading 3.9% Higher – Here’s What Happened

Senseonics Holdings, Inc. (NYSE:SENS) rose 3.9% on Thursday . The company traded as high as $7.68 and last traded at $7.51. Approximately 318,645 shares traded hands during mid-day trading, a decline of 26% from the average daily volume of 432,989 shares. The stock had previously closed at $7.23.

Wall Street Analysts Forecast Growth

SENS has been the topic of a number of recent analyst reports. TD Cowen reissued a “buy” rating on shares of Senseonics in a research report on Thursday, January 8th. HC Wainwright upped their target price on shares of Senseonics to $18.50 and gave the stock a “buy” rating in a report on Thursday, November 6th. Stifel Nicolaus started coverage on shares of Senseonics in a report on Tuesday, October 21st. They set a “hold” rating and a $9.00 price objective on the stock. Finally, Barclays restated an “overweight” rating and set a $31.00 target price (up previously from $1.50) on shares of Senseonics in a research report on Wednesday, November 5th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Senseonics presently has a consensus rating of “Buy” and a consensus price target of $22.70.

Senseonics Price Performance

The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.38 and a current ratio of 2.47. The company has a fifty day moving average price of $6.43 and a two-hundred day moving average price of $8.08. The company has a market cap of $298.68 million, a P/E ratio of -56.23 and a beta of 0.63.

Insider Activity

In other news, CFO Frederick T. Sullivan acquired 5,415 shares of the stock in a transaction dated Friday, November 7th. The shares were bought at an average cost of $5.88 per share, for a total transaction of $31,840.20. Following the purchase, the chief financial officer directly owned 157,028 shares of the company’s stock, valued at approximately $923,324.64. This trade represents a 3.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Douglas A. Roeder acquired 15,000 shares of the company’s stock in a transaction on Friday, November 7th. The stock was acquired at an average price of $5.83 per share, for a total transaction of $87,450.00. Following the purchase, the director directly owned 99,727 shares of the company’s stock, valued at approximately $581,408.41. This trade represents a 17.70% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 30,415 shares of company stock valued at $184,790 in the last quarter. Company insiders own 3.60% of the company’s stock.

Institutional Trading of Senseonics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Townsend Asset Management Corp NC ADV bought a new stake in shares of Senseonics in the fourth quarter valued at approximately $60,000. Smith Salley Wealth Management lifted its position in shares of Senseonics by 10.9% during the 3rd quarter. Smith Salley Wealth Management now owns 61,000 shares of the company’s stock valued at $27,000 after acquiring an additional 6,000 shares during the period. Elite Life Management LLC bought a new stake in shares of Senseonics during the 2nd quarter valued at $36,000. HBK Sorce Advisory LLC acquired a new stake in shares of Senseonics during the 3rd quarter worth $39,000. Finally, Ausdal Financial Partners Inc. increased its position in shares of Senseonics by 50.0% in the third quarter. Ausdal Financial Partners Inc. now owns 105,000 shares of the company’s stock worth $46,000 after purchasing an additional 35,000 shares during the period. Institutional investors and hedge funds own 12.36% of the company’s stock.

Senseonics Company Profile

Senseonics Holdings, Inc is a medical technology company focused on the development and commercialization of innovative continuous glucose monitoring (CGM) systems for people with diabetes. Since its founding in 2011 and headquartered in Germantown, Maryland, the company has pioneered an implantable sensor designed to deliver long-term glucose readings. Senseonics’ mission centers on improving diabetes management by providing accurate, real-time data to patients and healthcare providers.

The company’s flagship offering is the Eversense CGM System, which features a small, fully implantable sensor placed beneath the skin to measure glucose levels for up to 90 days in the United States and up to 180 days in Europe.